Cure8 research brief
Early-stage research suggests a specific probiotic strain may reduce inflammation and alter the gut microbiome and immune-related proteins in an animal model of ulcerative colitis, which could point to future therapeutic research directions.
Researchers in microbiome and immunology, clinicians following probiotic research, and patients interested in emerging preclinical work on probiotics for UC.
This article reports an animal-model study testing an infant-derived probiotic strain, Lactiplantibacillus plantarum BF_15, in a dextran-sodium-sulfate (DSS) model of ulcerative colitis.
The abstract summarizes physiological, microbiome, and proteomic findings: BF_15 reduced disease activity scores, limited weight loss and colon shortening, altered inflammatory cytokines (lower IL-6/IL-17A, higher IL-10 and SIgA), shifted gut microbial composition, and changed expression of hundreds of proteins with effects on antigen presentation pathways.
The authors compared BF_15 with Lactobacillus rhamnosus GG (LGG) and report comparable or superior effects in several readouts. The study is preclinical (animal) and uses proteomics and microbiome sequencing to explore mechanisms rather than report human outcomes.
These findings suggest BF_15 may be a candidate for further preclinical and eventual clinical research but do not establish safety or efficacy in people with UC.
Findings are from a DSS animal model with molecular and microbiome analyses (abstract-level summary). This does not constitute evidence of safety or efficacy in humans; clinical trials would be required.
Review the original publication for the complete reporting, methods, and context.
Conflict statement: Co‐authors Hongyan Kang and Miaoshu Wang are employed by New Hope Tensun (Hebei) Dairy Co. Ltd. and act as off‐campus supervisors of the affiliated university. They provided auxiliary technical support for this study based on industrial practical experience, including experimental validation, data curation, and figure visualization. Their affiliated company did not provide any financial support, experimental supplies, or laboratory resources for this study. The patent of strain BF_15 (No. ZL202010193432.4) is exclusively owned by the university of the corresponding institution. No commercial development or industrial translation of strain BF_15 has been conducted so far. The other authors declare no conflicts of interest.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The findings suggest a processed herbal/tea preparation may alter gut metabolites and microbes to reduce colitis in mice, which could guide future dietary or translational research relevant to people with ulcerative...
The review proposes a low-cost, non-immunosuppressive adjunctive strategy targeting the gut microbiome and luminal metabolism to help maintain remission in UC, an area of strong patient interest but limited clinical...
Diet is a modifiable factor that could influence IBD risk through effects on the gut microbiome and immune pathways.
